Annovis Bio (ANVS)

• Market cap: $73.2M
• 1 day: 4.24%
• 5 days: -3.37%
• 1 month: -16.5%
• 3 months: -20%
• 6 months: -52.22%
• Year to date: -52.88%
• 1 year: -20.74%
• 5 years: -98.03%
• 10 years: -82.06%
• Sector: Healthcare
• Industry: Biotechnology

About: Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Employees: 7